Targeting the HIV-protease in AIDS therapy: a current clinical perspective.
about
Multiple routes and milestones in the folding of HIV-1 protease monomerIdentification of novel HIV 1--protease inhibitors: application of ligand and structure based pharmacophore mapping and virtual screeningComputational study of the resistance shown by the subtype B/HIV-1 protease to currently known inhibitors.Multi-target QSAR modelling in the analysis and design of HIV-HCV co-inhibitors: an in-silico study.Adverse metabolic consequences of HIV protease inhibitor therapy: the search for a central mechanism.Delivery of novel macromolecular drugs against HIV-1.Towards tricking a pathogen's protease into fighting infection: the 3D structure of a stable circularly permuted onconase variant cleavedby HIV-1 proteaseNon-nucleoside inhibitors of herpesviruses.Protease Inhibitors for Patients With HIV-1 Infection: A Comparative Overview.Synergistic interactions of the antiretroviral protease inhibitors saquinavir and ritonavir with chloroquine and mefloquine against Plasmodium falciparum in vitro.Insight into the folding inhibition of the HIV-1 protease by a small peptideNovel method for probing the specificity binding profile of ligands: applications to HIV protease.Investigation of the alkenyldiarylmethane non-nucleoside reverse transcriptase inhibitors as potential cAMP phosphodiesterase-4B2 inhibitorsProtein-ligand docking: current status and future challenges.Resilience to resistance of HIV-1 protease inhibitors: profile of darunavir.Plasmodium falciparum: new molecular targets with potential for antimalarial drug development.Protease sensing with nanoparticle based platforms.Role of darunavir in the management of HIV infection.Delivery of Therapeutic Proteins Using Electrospun Fibers-Recent Developments and Current Challenges.Exploring the subsite specificity of Schistosoma mansoni aspartyl hemoglobinase through comparative molecular modelling.Cell-based fluorescence assay for human immunodeficiency virus type 1 protease activityStructural requirements for potential HIV-integrase inhibitors identified using pharmacophore-based virtual screening and molecular dynamics studies.Structure-based phenotyping predicts HIV-1 protease inhibitor resistance.Design of HIV-1-PR inhibitors that do not create resistance: blocking the folding of single monomers.Automated docking to multiple target structures: incorporation of protein mobility and structural water heterogeneity in AutoDock.Evolutionary analysis of HIV-1 protease inhibitors: Methods for design of inhibitors that evade resistance.Resistance profiles of cyclic and linear inhibitors of HIV-1 protease.The molecular evolution of HIV-1 protease simulated at atomic detail.Inhibitors of HIV-1 protease: 10 years afterDesign of a folding inhibitor of the HIV-1 protease
P2860
Q28475755-567587D5-ED04-4B83-B8E8-34D2A182E563Q28485115-BBEC316B-A856-4048-842C-F69C4917C95BQ33563075-4B7A0522-7A83-4FC8-911D-ED8A9ED8F1C7Q33966485-E5845A4E-3D14-4543-99AF-2F6E58C71AFCQ34187120-B7827342-5849-465E-BEAF-015382F53D86Q34452681-EDAD4166-BBF6-4854-BEB4-38C737259441Q34563323-FC4F6D7D-2838-4CE7-AA6A-11614B944536Q34622466-38FA3346-86A1-4A52-BAFE-E58FDAD55EF2Q34631149-F9449BE2-820B-4541-9EDE-B249756C5EF6Q35636034-3C52319B-EABF-451C-A082-0C645F44B016Q36008703-EE4CA21C-C514-41FE-8FAC-72F255AA5B19Q36344445-7A077C60-369E-4D96-847E-621554F37D9DQ36499463-59B696C8-9123-453E-AFFA-11213A0A2C2BQ36544700-E5942AB1-4035-4F4F-A91A-0D22E5A466ACQ37235740-67947CEF-6068-4DF2-98B5-54F19A4538ECQ37626063-86AF6A51-D3F6-4B45-A9D9-A4DE43AF86D1Q37793922-B3C66BD6-2301-4BEC-B266-7718648C1687Q37957871-1481606E-8151-45D0-9C05-CE59DDE4FD4BQ38636785-B9F20825-30CE-4630-BD1D-1369943931A2Q39462950-B4C4F1BD-B27D-4C84-8CD9-3E00524406E4Q39478324-D6B81066-CD6E-432D-93A1-95741245D456Q40818771-5054D8AC-7FE8-4D60-A97D-1A67F2E73F33Q41815076-3BF20827-5956-4E52-9D41-DF724DBD3B2DQ43057874-B36A16A4-0B50-4D01-8773-07857BE0109DQ43825573-98D81C2B-20A6-4CDA-AD5B-5C2AD74DDE30Q43994824-913B2A47-2872-47D7-B055-A498CA95B1C9Q44103468-F39850B9-335C-4BA2-B4D8-A2D4AADC6713Q51762113-5A15914B-9FC3-4F43-A6FA-451D10A000EBQ58389026-BE04B16E-3853-439B-99E0-D09150851DB9Q58882322-8A478A33-13B2-46A2-B25B-1AC186B3F32E
P2860
Targeting the HIV-protease in AIDS therapy: a current clinical perspective.
description
2000 nî lūn-bûn
@nan
2000 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի մարտին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Targeting the HIV-protease in AIDS therapy: a current clinical perspective.
@ast
Targeting the HIV-protease in AIDS therapy: a current clinical perspective.
@en
type
label
Targeting the HIV-protease in AIDS therapy: a current clinical perspective.
@ast
Targeting the HIV-protease in AIDS therapy: a current clinical perspective.
@en
prefLabel
Targeting the HIV-protease in AIDS therapy: a current clinical perspective.
@ast
Targeting the HIV-protease in AIDS therapy: a current clinical perspective.
@en
P1476
Targeting the HIV-protease in AIDS therapy: a current clinical perspective.
@en
P2093
A G Tomasselli
R L Heinrikson
P304
P356
10.1016/S0167-4838(99)00273-3
P407
P577
2000-03-01T00:00:00Z